Summarized by Masters of Longevity from PR Newswire.
A conference and journal report you can open to learn about a late‑stage clinical trial testing a new antibody‑drug conjugate plus immunotherapy in first‑line lung cancer patients. It previews study design, clinical context, and trial presentation/publication details to help you decide whether to read the full results.
Key Takeaways
- Sacituzumab tirumotecan plus pembrolizumab reduced progression or death risk by fifty percent.
- Median progression-free survival was fifteen months with the ADC plus pembrolizumab.
- The ADC combination showed generally consistent safety with fewer high-grade adverse events.
